pramipexole

(redirected from Pramipexole dihydrochloride)
Also found in: Medical.
Related to Pramipexole dihydrochloride: Parkinson's disease, Restless Leg Syndrome, Mirapex

pram·i·pex·ole

 (prăm′ə-pĕk′sōl′)
n.
A dopamine agonist used in the treatment of Parkinson's disease.

[pr(opyl) + ami(no) + pex-, of unknown meaning + (thiaz)ole.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

pramipexole

n pramipexol m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Patients were randomized 1:1 to receive branded pramipexole dihydrochloride (Mirapex[R] IR, Boehringer Ingelheim, Ridgefield, CT) or ropinirole hydrochloride (Requip[R] IR, GlaxoSmithKline, Research Triangle Park, NC) through retail pharmacies.
Pramipexole Dihydrochloride Tablets, the generic version of Mirapex, is available in 0.125-, 0.25-, 0.5-, 0.75-, 1- and 1.5-milligram 90-count bottles.
Pramipexole dihydrochloride tablets, the generic version of Mirapex, is available in 0.125, 0.25, 0.5, 0.75, 1 and 1.5 mg 90-count bottles and is used to treat the signs and symptoms of Parkinson's disease as well as treating restless legs syndrome (RLS).
Reddy's Laboratories (NYSE:RDY) revealed on Wednesday the availability of the US Food & Drug Administration (USFDA) approved PRAMIPEXOLE dihydrochloride extended-release tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in the US market on 11 August 2015.
Patients reporting reward-based behaviors were more likely than were others to be taking combinations of medications, especially Sinemet (carbidopa/levodopa) and Mirapex (pramipexole dihydrochloride).
Patients reporting reward-based behaviors were more likely than were other patients to be taking combinations of medications, especially Sinemet (carbidopa/levodopa) and Mirapex (pramipexole dihydrochloride).
says its subsidiary, Mylan Pharmaceuticals Inc., has received final approval of its ANDA for pramipexole dihydrochloride tablets in 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 1.5 mg doses.
Pharmaceutical firm Mylan Inc (Nasdaq:MYL) declared on Thursday that its subsidiary Mylan Pharmaceuticals Inc has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pramipexole Dihydrochloride Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 1.5 mg for the treatment of Parkinson's disease.